- Eli Lilly's Surmount-5: Zepbound patients lost ~20.2% body weight (~50 lb) vs Wegovy's 13.7% (~33 lb); newer higher-dose Wegovy study shows ~47 lb loss.
- Novo Nordisk sued Eli Lilly in U.S. court alleging false advertising and unfair competition over Lilly’s national campaigns for Zepbound and Mounjaro, seeking injunctions, corrective ads and damages.
- Eli Lilly agreed to buy AtaiBeckley, acquiring a rapid-acting neuroplastogen pipeline led by BPL-003 for treatment‑resistant depression, expanding Lilly’s mental‑health asset and development programs
TradingView
Key facts: Zepbound tops Wegovy; Novo sues; Lilly buys AtaiBeckley
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NYSE:LLY
- Language
- English
Eli Lilly's Surmount-5: Zepbound patients lost ~20.2% body weight (~50 lb) vs Wegovy's 13.7% (~33 lb); newer higher-dose Wegovy study shows ~47 lb loss.Novo Nordisk sued Eli Lilly